Review



cd39 blocking antibody iph520  (Innate Pharma)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Innate Pharma cd39 blocking antibody iph520
    Effects of targeting <t>CD39</t> on T cells. ( A ) CD39 or CD73 blocking by pharmacological compounds (i.e., POM1 and ARL7156 or small-molecule inhibitors) or by using antibodies in in vivo systems decreases the suppressive activities of FOXP3 + Treg cells. ( B ) Targeting CD39 or CD73 in CD8 T cells effects an increase in effector and cytotoxic T cell functions, mediated by IFN-γ and TNF-α production and CD107a upregulation. ( C ) Targeting CD39 or CD73 in CD4 T cells increases Th1 cytokine (IFN-γ, TNF-α and IL-2) and IL-21 production, which (was recently found to be) is responsible for B cell differentiation.
    Cd39 Blocking Antibody Iph520, supplied by Innate Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd39 blocking antibody iph520/product/Innate Pharma
    Average 90 stars, based on 1 article reviews
    cd39 blocking antibody iph520 - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "CD39 Regulation and Functions in T Cells"

    Article Title: CD39 Regulation and Functions in T Cells

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms22158068

    Effects of targeting CD39 on T cells. ( A ) CD39 or CD73 blocking by pharmacological compounds (i.e., POM1 and ARL7156 or small-molecule inhibitors) or by using antibodies in in vivo systems decreases the suppressive activities of FOXP3 + Treg cells. ( B ) Targeting CD39 or CD73 in CD8 T cells effects an increase in effector and cytotoxic T cell functions, mediated by IFN-γ and TNF-α production and CD107a upregulation. ( C ) Targeting CD39 or CD73 in CD4 T cells increases Th1 cytokine (IFN-γ, TNF-α and IL-2) and IL-21 production, which (was recently found to be) is responsible for B cell differentiation.
    Figure Legend Snippet: Effects of targeting CD39 on T cells. ( A ) CD39 or CD73 blocking by pharmacological compounds (i.e., POM1 and ARL7156 or small-molecule inhibitors) or by using antibodies in in vivo systems decreases the suppressive activities of FOXP3 + Treg cells. ( B ) Targeting CD39 or CD73 in CD8 T cells effects an increase in effector and cytotoxic T cell functions, mediated by IFN-γ and TNF-α production and CD107a upregulation. ( C ) Targeting CD39 or CD73 in CD4 T cells increases Th1 cytokine (IFN-γ, TNF-α and IL-2) and IL-21 production, which (was recently found to be) is responsible for B cell differentiation.

    Techniques Used: Blocking Assay, In Vivo, Cell Differentiation



    Similar Products

    cd39 blocking antibody iph520  (Innate Pharma)
    90
    Innate Pharma cd39 blocking antibody iph520
    Effects of targeting <t>CD39</t> on T cells. ( A ) CD39 or CD73 blocking by pharmacological compounds (i.e., POM1 and ARL7156 or small-molecule inhibitors) or by using antibodies in in vivo systems decreases the suppressive activities of FOXP3 + Treg cells. ( B ) Targeting CD39 or CD73 in CD8 T cells effects an increase in effector and cytotoxic T cell functions, mediated by IFN-γ and TNF-α production and CD107a upregulation. ( C ) Targeting CD39 or CD73 in CD4 T cells increases Th1 cytokine (IFN-γ, TNF-α and IL-2) and IL-21 production, which (was recently found to be) is responsible for B cell differentiation.
    Cd39 Blocking Antibody Iph520, supplied by Innate Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd39 blocking antibody iph520/product/Innate Pharma
    Average 90 stars, based on 1 article reviews
    cd39 blocking antibody iph520 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Effects of targeting CD39 on T cells. ( A ) CD39 or CD73 blocking by pharmacological compounds (i.e., POM1 and ARL7156 or small-molecule inhibitors) or by using antibodies in in vivo systems decreases the suppressive activities of FOXP3 + Treg cells. ( B ) Targeting CD39 or CD73 in CD8 T cells effects an increase in effector and cytotoxic T cell functions, mediated by IFN-γ and TNF-α production and CD107a upregulation. ( C ) Targeting CD39 or CD73 in CD4 T cells increases Th1 cytokine (IFN-γ, TNF-α and IL-2) and IL-21 production, which (was recently found to be) is responsible for B cell differentiation.

    Journal: International Journal of Molecular Sciences

    Article Title: CD39 Regulation and Functions in T Cells

    doi: 10.3390/ijms22158068

    Figure Lengend Snippet: Effects of targeting CD39 on T cells. ( A ) CD39 or CD73 blocking by pharmacological compounds (i.e., POM1 and ARL7156 or small-molecule inhibitors) or by using antibodies in in vivo systems decreases the suppressive activities of FOXP3 + Treg cells. ( B ) Targeting CD39 or CD73 in CD8 T cells effects an increase in effector and cytotoxic T cell functions, mediated by IFN-γ and TNF-α production and CD107a upregulation. ( C ) Targeting CD39 or CD73 in CD4 T cells increases Th1 cytokine (IFN-γ, TNF-α and IL-2) and IL-21 production, which (was recently found to be) is responsible for B cell differentiation.

    Article Snippet: Similarly, a CD39 blocking antibody (IPH520) was recently developed by Innate Pharma and entered in a recent clinical trial (NCT04261075) with the objective of studying IPH5201 as a monotherapy or in combination with anti-PDL1 (Durvalumab) and/or anti-CD73 (Oleclumab).

    Techniques: Blocking Assay, In Vivo, Cell Differentiation